You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR CHLORPHENIRAMINE MALEATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Chlorpheniramine Maleate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00555542 ↗ An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis Completed Chinese University of Hong Kong Phase 2 2006-07-01 To study the effects of T cell in peripheral blood of patients with RA undergoing selective B cell depletion have not been studied. We analyze the B and T cell subsets in patients with active RA treated undergoing this form of treatment with rituximab.
NCT00837837 ↗ Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2008-12-21 The purpose of this study is to examine the pharmacokinetic parameters of chlorpheniramine in children and adolescents.
NCT01158326 ↗ Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu Completed Hospital de Clinicas de Porto Alegre Phase 3 2010-08-01 This study aimed to evaluate the efficacy and safety of the oral solution of paracetamol, chlorpheniramine maleate and phenylephrine hydrochloride in reducing symptoms of flu and the common cold. There will be a randomized, double-blind, placebo-controlled trial. Will be included 216 subjects, male or female, aged greater than 12 and less than or equal to 60 years, irrespective of color and / or race with symptoms of recent onset, for more than 6 hours and less than 48 hours length, characterizing Common Cold and / or Influenza. After clinical evaluation and laboratory research subjects will be randomized to receive active drug or placebo, 10 ml oral solution every 6 hours for 48 hours. The follow-up visits will be held on 2 (24 hours after first intervention) and in 3 days (48 hours after first intervention). The outcomes to assess the effectiveness so far consist of the scores of symptoms and to assess the safety of the drug will be accompanied by the emergence of adverse events.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Chlorpheniramine Maleate

Condition Name

Condition Name for Chlorpheniramine Maleate
Intervention Trials
Common Cold 2
Coronavirus Disease 2019 1
Symptoms and Signs 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Chlorpheniramine Maleate
Intervention Trials
Rhinitis 3
Rhinitis, Allergic 2
Common Cold 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Chlorpheniramine Maleate

Trials by Country

Trials by Country for Chlorpheniramine Maleate
Location Trials
United States 8
Brazil 2
China 2
Honduras 1
Mauritius 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Chlorpheniramine Maleate
Location Trials
Florida 1
Texas 1
South Carolina 1
Ohio 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Chlorpheniramine Maleate

Clinical Trial Phase

Clinical Trial Phase for Chlorpheniramine Maleate
Clinical Trial Phase Trials
Phase 4 1
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Chlorpheniramine Maleate
Clinical Trial Phase Trials
Completed 7
Terminated 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Chlorpheniramine Maleate

Sponsor Name

Sponsor Name for Chlorpheniramine Maleate
Sponsor Trials
Magna Pharmaceuticals, Inc. 1
Ache Laboratorios Farmaceuticos S.A. 1
Sino-American Tianjin Smith Kline & French Laboratories Ltd 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Chlorpheniramine Maleate
Sponsor Trials
Industry 6
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Chlorpheniramine Maleate: Clinical Trials, Market Analysis, and Projections

Introduction

Chlorpheniramine maleate, a first-generation antihistamine, is widely used to alleviate symptoms of allergic conditions such as allergic rhinitis, hay fever, and common cold. This article delves into recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Efficacy in Catheter-Related Bladder Discomfort

A randomized, controlled trial investigated the efficacy of chlorpheniramine maleate (CPM) in reducing catheter-related bladder discomfort (CRBD) in patients undergoing ureteroscopic stone removal. The study found that CPM significantly reduced the severity and incidence of CRBD, particularly in the early hours post-procedure. The anticholinergic effects of CPM were hypothesized to be the primary mechanism behind this reduction[1].

Efficacy in Allergic Rhinitis and Common Cold

A double-blind, placebo-controlled clinical trial evaluated the efficacy of chlorpheniramine in relieving symptoms of a rhinovirus-induced common cold. The study showed that chlorpheniramine significantly reduced symptom scores, particularly for sneezing, and improved mucociliary clearance rates compared to the placebo group. However, no significant differences were observed in objective measures of nasal congestion or middle ear and eustachian tube responses[4].

Market Analysis

Market Size and Growth

The chlorpheniramine maleate market is projected to experience significant growth over the coming years. As of 2022, the market size was valued at $468.6 million and is expected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032[3][5].

Market Segmentation

The market can be segmented by product form, including injections, syrups, tablets, and powders. The injection segment held the largest market share in 2021, driven by its application in treating acute urticaria and hay fever. However, the tablets segment is expected to grow with the fastest CAGR of 4.8% during the forecast period due to its expanding use in alleviating allergy symptoms[2].

Geographical Analysis

North America currently dominates the market, attributed to advanced healthcare infrastructure and easy access to healthcare services, including over-the-counter (OTC) medications for allergic conditions. However, the Asia-Pacific region is expected to witness the highest growth rate, driven by increasing urbanization, rising air pollution, and a growing geriatric population in countries like India, China, Japan, and South Korea[3][5].

Distribution Channels

The market is also segmented by distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies exhibited the highest growth in 2022 and are expected to lead during the forecast period. Online pharmacies, however, are anticipated to witness considerable growth due to increased consumer awareness and the easy availability of chlorpheniramine maleate[5].

Market Drivers

Rising Prevalence of Allergies

The increasing prevalence of allergic conditions such as allergic rhinitis and urticaria is a key driver of the chlorpheniramine maleate market. For instance, approximately 81 million people in the U.S. were diagnosed with seasonal allergic rhinitis in 2021, which equals around 26% of adults and 19% of children[3].

Advances in Pharmaceutical Technology

Advances in pharmaceutical technology, including the development of new formulations such as extended-release tablets and liquid formulations, are expected to enhance efficacy, convenience, and patient compliance, thereby driving market growth[3].

Increased Demand for Antihistamines

A surge in demand for antihistamines, coupled with increased investments in R&D activities by pharmaceutical companies, is also propelling the market forward[3].

Market Challenges

Side Effects and Alternative Medications

Despite the growth prospects, the market faces challenges such as potential side effects of chlorpheniramine maleate, including drowsiness, dry mouth, blurred vision, and urinary retention. Additionally, the availability of alternative medications and a shift towards natural remedies and holistic approaches could hamper market growth[3].

Future Projections

Regional Growth

The Asia-Pacific region is expected to grow at the highest CAGR of 5.5% by 2032, driven by factors such as rising urbanization, increasing air pollution, and a growing geriatric population. North America is anticipated to remain dominant during the forecast period due to its advanced healthcare infrastructure and high prevalence of allergic conditions[5].

Segmental Growth

The allergic rhinitis segment is expected to witness the fastest CAGR during the forecast period, driven by an increase in the prevalence of allergic rhinitis and a surge in demand for antihistamines[5].

Key Takeaways

  • Chlorpheniramine maleate has shown efficacy in reducing catheter-related bladder discomfort and alleviating symptoms of allergic rhinitis and common cold.
  • The market is projected to grow from $468.6 million in 2022 to $751.4 million by 2032, with a CAGR of 4.9%.
  • The Asia-Pacific region is expected to witness the highest growth rate, driven by urbanization, air pollution, and a growing geriatric population.
  • Advances in pharmaceutical technology and increasing demand for antihistamines are key market drivers.
  • Potential side effects and the availability of alternative medications are significant market challenges.

FAQs

What is chlorpheniramine maleate used for?

Chlorpheniramine maleate is used to treat various allergic conditions, including allergic rhinitis (hay fever), red, itchy, watery eyes, sneezing, itchy nose or throat, and runny nose caused by allergies and the common cold[3].

What are the common side effects of chlorpheniramine maleate?

Common side effects include drowsiness, dry mouth, blurred vision, and urinary retention[3].

How does chlorpheniramine maleate work?

Chlorpheniramine maleate works by binding to the histamine H1 receptor, blocking the action of endogenous histamine and providing temporary relief from allergic symptoms[3].

What is the market size of chlorpheniramine maleate expected to be by 2032?

The market size is projected to reach $751.4 million by 2032, growing at a CAGR of 4.9% from 2023 to 2032[3][5].

Which region is expected to witness the highest growth rate in the chlorpheniramine maleate market?

The Asia-Pacific region is expected to witness the highest growth rate, driven by factors such as urbanization, air pollution, and a growing geriatric population[5].

Sources

  1. Effects of Chlorpheniramine Maleate on Catheter-Related Bladder Discomfort in Patients Undergoing Ureteroscopic Stone Removal. MedSci.
  2. Chlorpheniramine Maleate Market - Forecast(2025 - IndustryARC.
  3. Chlorpheniramine Maleate Market Statistics and Forecast - 2032. Allied Market Research.
  4. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the symptoms and pathophysiologic correlates of a rhinovirus "common cold". PubMed.
  5. Chlorpheniramine Maleate Market | $751.4 Million by 2032. Allied Market Research.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.